4-in-1 Grant Program; Correction, 25682-25683 [2016-10164]
Download as PDF
<![CDATA[
25682
Federal Register / Vol. 81, No. 83 / Friday, April 29, 2016 / Notices
Information Collection Request Title:
Office on Women’s Health: IPV
Provider Network Cross-Site Evaluation
Abstract: The Affordable Care Act
(PHS 2713) requires health insurance
plans to cover preventive care and
screening for women as defined by the
Health Resources and Services
Administration (HRSA) Women’s
Preventive Services Guidelines,
including screening and counseling for
interpersonal and domestic violence. In
addition, the U.S. Preventive Services
Task Force released a recommendation
for IPV (interpersonal violence)
screening in clinical settings. As part of
the administration’s efforts to create a
health system that better addresses the
needs of IPV victims, the Office on
Women’s Health (OWH) at the U.S.
Department of Health and Human
Services has established the IPV
Provider Network program. The
program requires partnerships between
health care providers and IPV service
programs to evaluate systems for
integrating IPV interventions into basic
clinical care. Each of the five selected
OWH grantees is required to establish
Memoranda of Understanding with 5 to
10 partners that provide services (e.g.,
legal, housing, substance use, mental
health) to clients referred by the grantee
health providers. The overall goal of the
IPV Provider Network project is to
understand and assess the strategies
implemented by the five different IPV
Provider Network programs designed to
improve care coordination for IPV
screening/referred patients. OWH will
use program assessment findings to
support future work with federal and
state partners to disseminate the
evidence-based strategies that are
created. The purpose of this data
collection is to gather data from the
grantees’ service provider partners to
answer the research question: What
feedback is available from the service
partners to refine the IPV referral and
follow-up processes? OWH contractor
NORC at the University of Chicago will
collect and analyze two sources of
primary data. The first data source will
be a brief online survey administered to
a single representative of each of the
partners, assessing (a) the partnership
with the respective OWH grantee’s
health care provider and (b) the services
that partner provides to the women
referred by the health care provider. The
second data source is a key informant
interview with a single representative of
each partner, providing a mechanism for
the key informant to elaborate on their
agency’s survey response data. Direct
contact with the partners is necessary to
understand the nature of each grantee’s
provider network partnerships,
including what works and what does
not work.
Likely Respondents: Medical and
Health Services Managers.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Number of
responses
per
respondent
Average
burden per
response
(in hours)
Total burden
hours
Semi-annual online Service Provider Assessments ........................................
Key informant interviews .................................................................................
50
50
2
1
30/60
1
50/60
50/60
Total ..........................................................................................................
........................
........................
........................
100
OS specifically requests comments on
(1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Register on March 14, 2016, for the FY
2016 4-in-1 Grant Program. The notice
contained incorrect page limits for one
section of the project narrative and the
overall project narrative.
FOR FURTHER INFORMATION CONTACT: Rick
Mueller, Public Health Advisor, Office
of Urban Indian Health Programs, 5600
Fishers Lane, Mail Stop: 08E65B,
Rockville, MD 20857, Telephone (301)
443–4680. (This is not a toll-free
number.)
Terry S. Clark,
Asst. Information Collection Clearance
Officer.
Corrections
In the Federal Register of March 14,
2016, in FR Doc. 2016–05761, the
following corrections are made:
1. On page 13382, in the first column,
under the heading ‘‘IV. Application and
Submission Information, 2. Content and
Form of Application Submission’’, the
correct Project Narrative requirement
should read as ‘‘Project Narrative (must
be single-spaced and not exceed thirty
two pages)’’.
2. On page 13382, in the second
column, under the heading ‘‘IV.
Application and Submission
Information, Requirements for Project
and Budget Narratives, A. Project
Narrative’’, the correct paragraphs
[FR Doc. 2016–10066 Filed 4–28–16; 8:45 am]
BILLING CODE 4150–33–P
asabaliauskas on DSK3SPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Indian Health Service
4-in-1 Grant Program; Correction
Indian Health Service, HHS.
Notice; correction.
AGENCY:
ACTION:
The Indian Health Service
published a document in the Federal
SUMMARY:
VerDate Sep<11>2014
18:31 Apr 28, 2016
Jkt 238001
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
should read as ‘‘The project narrative
should be a separate Word document
that is no longer than 32 pages and
must: Be single-spaced, be type-written,
have consecutively numbered pages, use
black type not smaller than 12
characters per one inch, and be printed
on one side only of standard size 81⁄2 x
11 paper.
Be sure to succinctly address and
answer all questions listed under the
narrative and place them under the
evaluation criteria (refer to Section V.1,
Evaluation criteria in this
announcement) and place all responses
and required information in the correct
section (noted below), or they shall not
be considered or scored. These
narratives will assist the Objective
Review Committee (ORC) in becoming
familiar with the applicant’s activities
and accomplishments prior to this grant
award. If the narrative exceeds the page
limit, only the first 32 pages will be
reviewed. The 32-page limit for the
narrative does not include the table of
contents, abstract, standard forms,
budget justification narrative, and/or
other appendix items’’.
3. On page 13382, in the third
column, under the heading ‘‘IV.
E:\FR\FM\29APN1.SGM
29APN1
Federal Register / Vol. 81, No. 83 / Friday, April 29, 2016 / Notices
Application and Submission
Information, Requirements for Project
and Budget Narratives, A. Project
Narrative, Part A: Program Information
(3 Page Limitation)’’, the correct
subheading and page limit should read
as ‘‘Part A: Program Information (10
page limitation)’’.
4. On page 13384, in the first column,
under the heading ‘‘V. Application
Review Information’’, the correct
paragraph should read as ‘‘The
instructions for preparing the
application narrative also constitute the
evaluation criteria for reviewing and
scoring the application. Weights
assigned to each section are noted in
parentheses. The 32 page narrative
should include only the first year
activities; information for multi-year
projects should be included as an
appendix. See ‘‘Multi-year Project
Requirements’’ at the end of this section
for more information. The narrative
should be written in a manner that is
clear to outside reviewers unfamiliar
with prior related activities of the
applicant. It should be well organized,
succinct, and contain all information
necessary for reviewers to understand
the project fully. Points will be assigned
to each evaluation criteria adding up to
a total of 100 points. A minimum score
of 60 points is required for funding.
Points are assigned as follows:’’
Dated: April 25, 2016.
Elizabeth A. Fowler,
Deputy Director for Management Operations,
Indian Health Service.
[FR Doc. 2016–10164 Filed 4–28–16; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: AAV-Mediated Aquaporin
¨
Gene Transfer To Treat Sjogren’s
Syndrome
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive license to MeiraGTx,
having a principal place of business in
New York, New York, U.S.A. to practice
the inventions embodied in the
following patent applications, entitled
‘‘AAV-mediated aquaporin gene transfer
¨
to treat Sjogren’s syndrome’’:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:31 Apr 28, 2016
Jkt 238001
1. U.S. Provisional Patent Application No.
61/695,753 filed August 31, 2012 (HHS Ref.
No. E–139–2011/1–US–01);
2. PCT Application No. PCT/US2013/
057632, filed August 30, 2013 (HHS Ref. No.
E–139–2011/1–PCT–02);
3. Australia Patent Application No.
2013308470, filed February 25, 2015 (HHS
Ref. No. E–139–2011/1–AU–03);
4. Canada Patent Application No. 2882763,
filed February 20, 2015 (HHS Ref. No. E–
139–2011/1–CA–04);
5. European Patent Application No.
13773443.0, filed March 30, 2015 (HHS Ref.
No. E–139–2011/1–EP–05);
6. U.S. Patent Application No. 14/423,774,
filed February 25, 2015 (HHS Ref. No. E–
139–2011/1–US–06).
The patent rights in these inventions
have been assigned to the Government
of the United States of America. The
territory of the prospective license may
be worldwide, and the field of use may
be limited to adeno-associated virus
(AAV) vector mediated gene delivery of
human aquaporin-1 (hAQP1) in
¨
Sjogren’s syndrome patients with
associated xerostomia and/or
xerophthalmia.
DATES: Only written comments and/or
applications for a license that are
received by the National Institute of
Dental and Craniofacial Research, Office
of Technology Transfer and Innovation
Access on or before May 16, 2016 will
be considered.
FOR FURTHER INFORMATION CONTACT:
Requests for a copy of the patent
application(s), inquiries, comments and
other materials relating to the
contemplated license should be directed
to: Sally Hu, Ph.D., M.B.A., Senior
Licensing and Patenting Manager, Office
of Technology Transfer and Innovation
Access, National Institute of Dental and
Craniofacial Research, National
Institutes of Health, BLDG 1 DEM,
RM667, 6701 Democracy Blvd.,
Bethesda, MD 20817; Telephone: (301)
594–2616; Facsimile: (301) 496–1005;
Email: sally.hu@nih.gov. A signed
confidential disclosure agreement may
be required to receive copies of the
patent application assuming it has not
already been published under the
publication rules of either the United
States Patent and Trademark Office or
the World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION: This
subject technology is directed to the
methods of using AAV vectors to deliver
the hAQP gene into a salivary gland or
a lachrymal gland in patients who suffer
¨
¨
from Sjogren’s syndrome. Sjogren’s
syndrome is a systemic autoimmune
disease in which immune cells attack
and destroy the glands that produce
saliva and tears, resulting in progressive
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
25683
dry mouth and dry eyes. In a mouse
¨
model of Sjogren’s syndrome,
administration of hAQP–1 to salivary
glands can restore salivary secretion and
reduce inflammation in the glands.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license may be
granted unless, within fifteen (15) days
from the date of this published notice,
the Office of Technology Transfer and
Innovation Access, National Institute of
Dental and Craniofacial Research
receives written evidence and argument
that establishes that the grant of the
contemplated license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
Properly filed competing applications
for a license in the prospective field of
use that are filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: April 22, 2016.
David W. Bradley,
Director, Office of Technology Transfer and
Innovation Access, National Institute of
Dental and Craniofacial Research, National
Institutes of Health.
[FR Doc. 2016–09978 Filed 4–28–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel NIH
Blueprint Training in Computational
E:\FR\FM\29APN1.SGM
29APN1
]]>Agencies
[Federal Register Volume 81, Number 83 (Friday, April 29, 2016)]
[Notices]
[Pages 25682-25683]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-10164]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Indian Health Service
4-in-1 Grant Program; Correction
AGENCY: Indian Health Service, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Indian Health Service published a document in the Federal
Register on March 14, 2016, for the FY 2016 4-in-1 Grant Program. The
notice contained incorrect page limits for one section of the project
narrative and the overall project narrative.
FOR FURTHER INFORMATION CONTACT: Rick Mueller, Public Health Advisor,
Office of Urban Indian Health Programs, 5600 Fishers Lane, Mail Stop:
08E65B, Rockville, MD 20857, Telephone (301) 443-4680. (This is not a
toll-free number.)
Corrections
In the Federal Register of March 14, 2016, in FR Doc. 2016-05761,
the following corrections are made:
1. On page 13382, in the first column, under the heading ``IV.
Application and Submission Information, 2. Content and Form of
Application Submission'', the correct Project Narrative requirement
should read as ``Project Narrative (must be single-spaced and not
exceed thirty two pages)''.
2. On page 13382, in the second column, under the heading ``IV.
Application and Submission Information, Requirements for Project and
Budget Narratives, A. Project Narrative'', the correct paragraphs
should read as ``The project narrative should be a separate Word
document that is no longer than 32 pages and must: Be single-spaced, be
type-written, have consecutively numbered pages, use black type not
smaller than 12 characters per one inch, and be printed on one side
only of standard size 8\1/2\ x 11 paper.
Be sure to succinctly address and answer all questions listed under
the narrative and place them under the evaluation criteria (refer to
Section V.1, Evaluation criteria in this announcement) and place all
responses and required information in the correct section (noted
below), or they shall not be considered or scored. These narratives
will assist the Objective Review Committee (ORC) in becoming familiar
with the applicant's activities and accomplishments prior to this grant
award. If the narrative exceeds the page limit, only the first 32 pages
will be reviewed. The 32-page limit for the narrative does not include
the table of contents, abstract, standard forms, budget justification
narrative, and/or other appendix items''.
3. On page 13382, in the third column, under the heading ``IV.
[[Page 25683]]
Application and Submission Information, Requirements for Project and
Budget Narratives, A. Project Narrative, Part A: Program Information (3
Page Limitation)'', the correct subheading and page limit should read
as ``Part A: Program Information (10 page limitation)''.
4. On page 13384, in the first column, under the heading ``V.
Application Review Information'', the correct paragraph should read as
``The instructions for preparing the application narrative also
constitute the evaluation criteria for reviewing and scoring the
application. Weights assigned to each section are noted in parentheses.
The 32 page narrative should include only the first year activities;
information for multi-year projects should be included as an appendix.
See ``Multi-year Project Requirements'' at the end of this section for
more information. The narrative should be written in a manner that is
clear to outside reviewers unfamiliar with prior related activities of
the applicant. It should be well organized, succinct, and contain all
information necessary for reviewers to understand the project fully.
Points will be assigned to each evaluation criteria adding up to a
total of 100 points. A minimum score of 60 points is required for
funding. Points are assigned as follows:''
Dated: April 25, 2016.
Elizabeth A. Fowler,
Deputy Director for Management Operations, Indian Health Service.
[FR Doc. 2016-10164 Filed 4-28-16; 8:45 am]
BILLING CODE 4165-16-P
